HANK & LIN'S GROUP

The past is prologue and the future is scintillating

68Ga-P16-093: Second generation of PSMA imaging agent（IND# 133222）

Ga-68 labeled P16-093 for PSMA imaging: 68Ga-P16-093

Ga-68 labeled P16-093 for PSMA imaging: 68Ga-P16-093
PSMA-093: lower Bladder activity 低膀胱摄取、快速显像 （Phase II）

PSMA-093: lower Bladder activity 低膀胱摄取、快速显像 （Phase II）

5.Green,M. ,et al. “PSMA-targeted PET with [68Ga] Ga-P16-093: Initial evaluation in intermediate-risk and high-risk prostate cancer patients prior to prostatectomy”. Journal of Nuclear Medicine, 61(supplement 1), （2020）pp.192-192.

5.Green,M. ,et al. “PSMA-targeted PET with [68Ga] Ga-P16-093: Initial evaluation in intermediate-risk and high-risk prostate cancer patients prior to prostatectomy”. Journal of Nuclear Medicine, 61(supplement 1), （2020）pp.192-192.

4.Bahler, C., et al. “PSMA-targeted PET with [68Ga] Ga-P16-093: Assessment of potential role in surgical planning for patients with intermediate-risk and high-risk prostate cancer”. Journal of Nuclear Medicine, 61(supplement 1)（2020）1252-1252.

4.Bahler, C., et al. “PSMA-targeted PET with [68Ga] Ga-P16-093: Assessment of potential role in surgical planning for patients with intermediate-risk and high-risk prostate cancer”. Journal of Nuclear Medicine, 61(supplement 1)（2020）1252-1252.

  1. Wang, Guochang, Linlin Li, Jie Zang, Haiyan Hong, Lin Zhu, Hank F. Kung, and Zhaohui Zhu. "Head-to-Head Comparison of 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT in Patients With Primary Prostate Cancer: A Pilot Study." Clinical NuclearMedicine(2023);48: 289–295.
  2. Bahler, Clinton D., Mark A. Green, Mark A. Tann, Jordan K. Swensson, Katrina Collins, David Alexoff, Hank Kung et al."Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-care." InUrologic Oncology: Seminars and Original Investigations, vol. 41, no. 1, pp. 48-e1. Elsevier, 2023.
  3. Wang, Guochang, Linlin Li, Jiarou Wang, Jie Zang, Jingci Chen, Yu Xiao, Xinrong Fan, Lin Zhu, Hank F. Kung, and Zhaohui Zhu. "Head-to-head comparison of [68Ga] Ga-P16-093 and 2-[18F] FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study."European Journal of Nuclear Medicine and Molecular Imaging(2023): 1-11.
  4. Wang, Guochang, Linlin Li, Ming Zhu, Jiarou Wang, Rongxi Wang, Weigang Yan, Lin Zhu, Hank F Kung, Zhaohui Zhu. "A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer". European Journal of Nuclear Medicine and Molecular Imaging(2023) online
  5. Lee, Hwan, Joshua S. Scheuermann, Anthony J. Young, Robert K. Doot, Margaret E. Daube-Witherspoon, Erin K. Schubert, Matthew A. Fillare et al. "Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer." Molecular Imaging and Biology (2022): 1-11.
  6. Wang G, Hong H, Zang J, Liu Q, Jiang Y, Fan X, Zhu Z, Zhu L, Kung HF. Head-to-head comparison of [68Ga] Ga-P16-093 and [68Ga] Ga-PSMA-617 in dynamic PET/CT evaluation of the same group of recurrent prostate cancer patients. European journal of nuclear medicine and molecular imaging. 2022 Feb;49(3):1052-62
  7. Haiyan Hong, Guochang Wang, Karl Ploessl, Zhihao Zha, Jie Zang, Zhaohui Zhu, Lin Zhu, Hank F. Kung.,Kit-based preparation of [68Ga]Ga-P16-093 (PSMA-093) using different commercial 68Ge/68Ga generators, Nuclear Medicine and Biology 106 (2022):1-9
  8. Green, Mark A.，et al. "[68Ga] Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [68Ga] Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence." Molecular imaging and biology 22, no. 3 (2020): 752-763.
  9. Lee H, Scheuermann JS, Young AJ, Doot RK, Daube-Witherspoon ME, Schubert EK, Fillare MA, Alexoff D, Karp JS, Kung HF, Pryma DA. Preliminary Evaluation of 68Ga-P16-093, a PET Radiotracer Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. Molecular Imaging and Biology. 2022 Mar 29:1-11.
  10. Zha, Z., et al. "Synthesis and evaluation of a novel urea-based, 68Ga-complex for imaging PSMA binding in tumor". Nuclear Medicine and Biology, 2018, 59, 36–47.
  11. Zha, Zhihao, Seok Rye Choi, Karl Ploessl, David Alexoff, Ruiyue Zhao, Lin Zhu, and Hank F. Kung. "Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [18F] AlF-P16-093." Bioconjugate Chemistry 32, no. 5 (2021): 1017-1026.



    Publications:

    会议摘要：

    1. Wang J, Li L, Wang R, Zhou Z, Zhu L, Yan W, Kung H, Zhu Z. [68Ga] Ga-P16-093 Diagnostic Performance in Newly Diagnosed Prostate Cancer-Histopathologic Correlation. Journal of Nuclear MedicineJune 2024,65(supplement 2)241986
    2. Bahler C, Green M, Tann M, Collins K, Swensson J, Brocken E, Cheng L, Mathias C, Alexoff D, Kung H8 utchins G. PD27-01 PREDICTING EXTRA-PROSTATIC EXTENSION (EPE) FOR SURGICAL GUIDANCE IN PROSTATE CANCER: A COMPARISON OF BIOPSY PATHOLOGY, MULTIPARAMETRIC MRI, AND PSMA-PET. The Journal of Urology. 2022 May;207(Supplement 5):e493.7.
    3. Guochang Wang, Jie Zang, Haiyan Hong, Qingxing Liu, Yuanyuan Jiang, Zhaohui Zhu, Lin Zhu and Hank Kung. A pilot prospective comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617 in the same group of prostate cancer patients.Journal of Nuclear Medicine May 2021, 62 (supplement 1) 1329
    4. Green,M. ,et al. “PSMA-targeted PET with [68Ga] Ga-P16-093: Initial evaluation in intermediate-risk and high-risk prostate cancer patients prior to prostatectomy”. Journal of Nuclear Medicine, 61(supplement 1), （2020）pp.192
    5. Bahler, C., et al. “PSMA-targeted PET with [68Ga] Ga-P16-093: Assessment of potential role in surgical planning for patients with intermediate-risk and high-risk prostate cancer”. Journal of Nuclear Medicine, 61(supplement 1)（2020）1252
    6. Mark Green, Gary Hutchins, James Fletcher, Clint Bahler, Mark Tann, Justin Sims, Carla Mathias, Wendy Territo, Heather Polson, David Alexoff and Hank Kung. Initial evaluation of the PSMA-targeted PET agent [68Ga]Ga-P16-093, and comparison with [68Ga]Ga-PSMA-11, in prostate cancer patients presenting with biochemical recurrence.Journal of Nuclear Medicine May 2019, 60 (supplement 1) 9
    7. Robert, D., et al. "First in human experience with [68Ga] P16-093, a novel Ga-68 labeled Prostate Specific Membrane Antigen (PSMA) inhibitor." Journal of Nuclear Medicine 59, no. supplement 1 (2018): 52
    8. Choi, S., et al. "A new 68Ga Glu-Urea-Lys(Ahx)-HBED-CC derivative as an imaging agent for PSMA". Journal of Nuclear Medicine May 2018, 59 (supplement 1) 1113;
    9. Zhihao Zha, Zehui Wu, Seok Choi, Karl Ploessl, Lin Zhu and Hank Kung.New 68Ga Glu-Urea-Lys(Ahx)-HBED-CC Derivatives as Prostate Specific Membrane Antigen (PSMA) Imaging Agents.Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1366
    unsplash